NIP
OCUL icon

Nicholas Investment Partners’s Ocular Therapeutix OCUL Stock Holding History

Nicholas Investment Partners’s Portfolio OCUL Stock Details OCUL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q4 		– Sell
-62,669
Closed -$881K – 310
2015
Q3 		$881K Buy
+62,669
New +$1.26M 0.06% 285

Other funds holding OCUL

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
SHI
SV Health Investors Boston, Massachusetts $32.3M AUM 20.15% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
PVMCV
Polaris Venture Management Co V Boston, Massachusetts $14.1M AUM 121.41% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Nicholas Investment Partners's OCUL Position: Q4 2015 in Review

Nicholas Investment Partners sold out of Ocular Therapeutix (OCUL) in Q4 2015, closing a stake of 62,669 shares — an estimated $881K sold.

Nicholas Investment Partners first reported a position in OCUL in Q3 2015 and held it in 1 quarter. The position peaked at $881K in Q3 2015. 71 funds tracked by Wall St. Rank hold OCUL as of Q4 2015.

  • Nicholas Investment Partners reported no remaining Ocular Therapeutix position as of Q4 2015 after selling out during the quarter.
  • Nicholas Investment Partners sold 62,669 Ocular Therapeutix shares in Q4 2015, an estimated $881K.
  • Nicholas Investment Partners first reported a position in Ocular Therapeutix in Q3 2015 and held it in 1 quarter.
  • Nicholas Investment Partners's Ocular Therapeutix position peaked at $881K in Q3 2015.
  • 71 funds tracked by Wall St. Rank held Ocular Therapeutix as of Q4 2015.

Based on Nicholas Investment Partners's 13F filing for Q4 2015, filed 12 Feb 2016.